AstraZeneca: doubts about its effectiveness?
As 2020 was ending, the World has seen an influx of COVID-19 vaccines. AstraZeneca, which entered the European market on January 29 with its marketing authorization, has recently found itself suspended by several states. For reasons, the British-Swedish vaccine would align the adverse effects. Is this reversal, which occurred on March 11, justified?
The usefulness of the vaccine questioned
For a quick review, about ten countries have suspended the application of the AstraZeneca COVID-19 vaccine. This measure, which has taken place in recent days, has been implemented in various countries, particularly in Europe. These countries include Denmark, France, Bulgaria, Ireland, Austria, Thailand, Congo, etc.
The reasons put forward are that the vaccine would have significant negative health effects, related to the formation of blood clots. The European Medicines Agency has recorded about 30 cases of thrombosis in 5 million people vaccinated in the European Union. Even if the link between the vaccine and these problems is not yet clearly established, the authorities seem to take the issue very seriously.
A possible way out for AstraZeneca
In the clinical trials, only headache, injection site and muscle pain, fever, and fatigue were reported as side effects. The 3,013 reports of these effects out of the 454,000 vaccinations carried out in France as of March 4 was therefore normal in a certain sense. As for the problems of clot formation, circulation disorders, and thrombosis, they are unexpected.
The good news for AstraZeneca, as well as the various people who have been subjected to this treatment, is that there is not yet a proven link between the vaccine and these adverse events. Most of the prescriptions taken by the States are therefore preventive. AstraZeneca's efficacy rate of about 80% still makes it a strong ally in the fight against Covid-19. All that remains is to wait for the opinion of the European Medicines Agency, which could change the situation in the days to come.